Moody Aldrich Partners LLC Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

Moody Aldrich Partners LLC bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILDFree Report) during the 3rd quarter, Holdings Channel reports. The firm bought 5,858 shares of the biopharmaceutical company’s stock, valued at approximately $439,000.

Several other large investors also recently made changes to their positions in the business. Oppenheimer Asset Management Inc. grew its holdings in shares of Gilead Sciences by 3.5% during the third quarter. Oppenheimer Asset Management Inc. now owns 172,585 shares of the biopharmaceutical company’s stock worth $12,934,000 after purchasing an additional 5,798 shares during the last quarter. Kestra Private Wealth Services LLC boosted its holdings in Gilead Sciences by 3.5% in the third quarter. Kestra Private Wealth Services LLC now owns 39,388 shares of the biopharmaceutical company’s stock valued at $2,952,000 after acquiring an additional 1,319 shares during the last quarter. Hussman Strategic Advisors Inc. boosted its holdings in Gilead Sciences by 11.7% in the third quarter. Hussman Strategic Advisors Inc. now owns 42,000 shares of the biopharmaceutical company’s stock valued at $3,147,000 after acquiring an additional 4,400 shares during the last quarter. United Asset Strategies Inc. boosted its holdings in Gilead Sciences by 71.8% in the third quarter. United Asset Strategies Inc. now owns 49,101 shares of the biopharmaceutical company’s stock valued at $3,680,000 after acquiring an additional 20,520 shares during the last quarter. Finally, Quantbot Technologies LP bought a new position in Gilead Sciences in the third quarter valued at about $88,000. Institutional investors own 82.33% of the company’s stock.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 8,242 shares of the firm’s stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $85.23, for a total transaction of $702,465.66. Following the sale, the insider now owns 82,729 shares of the company’s stock, valued at $7,050,992.67. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, insider Johanna Mercier sold 8,242 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $85.23, for a total value of $702,465.66. Following the sale, the insider now owns 82,729 shares of the company’s stock, valued at approximately $7,050,992.67. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $85.78, for a total value of $428,900.00. Following the completion of the sale, the chief financial officer now directly owns 101,534 shares in the company, valued at approximately $8,709,586.52. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Analysts Set New Price Targets

GILD has been the topic of several recent research reports. Leerink Partnrs reiterated a “market perform” rating on shares of Gilead Sciences in a report on Wednesday, October 11th. UBS Group decreased their price target on Gilead Sciences from $85.00 to $84.00 and set a “neutral” rating on the stock in a report on Wednesday, November 8th. Royal Bank of Canada decreased their price target on Gilead Sciences from $78.00 to $77.00 and set a “sector perform” rating on the stock in a report on Tuesday, November 14th. Barclays raised their price target on Gilead Sciences from $82.00 to $85.00 and gave the company an “equal weight” rating in a report on Tuesday, January 23rd. Finally, Deutsche Bank Aktiengesellschaft started coverage on Gilead Sciences in a report on Thursday, November 9th. They set a “hold” rating and a $75.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Gilead Sciences presently has a consensus rating of “Hold” and a consensus target price of $87.20.

View Our Latest Stock Analysis on GILD

Gilead Sciences Trading Down 1.5 %

NASDAQ GILD opened at $76.96 on Friday. The firm has a market cap of $95.90 billion, a P/E ratio of 16.52, a P/E/G ratio of 0.93 and a beta of 0.20. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.34 and a quick ratio of 1.20. The stock’s 50-day moving average is $80.80 and its 200-day moving average is $78.32. Gilead Sciences, Inc. has a one year low of $72.87 and a one year high of $87.86.

Gilead Sciences (NASDAQ:GILDGet Free Report) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported $2.29 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.38. The company had revenue of $7.05 billion for the quarter, compared to analyst estimates of $6.81 billion. Gilead Sciences had a return on equity of 39.30% and a net margin of 21.45%. Gilead Sciences’s revenue was up .1% compared to the same quarter last year. During the same quarter last year, the firm posted $1.90 earnings per share. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 6.76 earnings per share for the current fiscal year.

Gilead Sciences Profile

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.

Featured Articles

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDFree Report).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.